You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 13, 2026

Suppliers and packagers for generic pharmaceutical drug: meloxicam; rizatriptan benzoate


✉ Email this page to a colleague

« Back to Dashboard


meloxicam; rizatriptan benzoate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Axsome SYMBRAVO meloxicam; rizatriptan benzoate TABLET;ORAL 215431 NDA Axsome Therapeutics, Inc. 81968-020-02 1 BOTTLE in 1 CARTON (81968-020-02) / 2 TABLET in 1 BOTTLE 2025-05-19
Axsome SYMBRAVO meloxicam; rizatriptan benzoate TABLET;ORAL 215431 NDA Axsome Therapeutics, Inc. 81968-020-03 1 BOTTLE in 1 CARTON (81968-020-03) / 3 TABLET in 1 BOTTLE 2025-05-19
Axsome SYMBRAVO meloxicam; rizatriptan benzoate TABLET;ORAL 215431 NDA Axsome Therapeutics, Inc. 81968-020-09 9 TABLET in 1 BOTTLE (81968-020-09) 2025-05-19
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drugs: Meloxicam and Rizatriptan Benzoate

Last updated: July 28, 2025

Introduction

The pharmaceutical supply chain depends heavily on reliable suppliers of active pharmaceutical ingredients (APIs). Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and Rizatriptan Benzoate, a selective serotonin receptor agonist used in migraine treatment, are critical components in therapeutic regimens worldwide. Ensuring a consistent supply involves understanding key manufacturers, geographic sourcing, and regulatory awareness. This report provides a comprehensive overview of primary suppliers for Meloxicam and Rizatriptan Benzoate, focusing on their manufacturing capacities, regulatory compliance, and market presence.


Overview of Meloxicam Suppliers

Global Manufacturing Landscape

Meloxicam APIs are produced predominantly in India, China, and Europe, reflecting the global pharmaceutical manufacturing footprint. Indian pharmaceutical companies are among the leading suppliers, supported by robust API manufacturing infrastructure and compliance with international standards.

Key Suppliers of Meloxicam

  1. Sun Pharmaceutical Industries Ltd. (India)
    Sun Pharma is one of the world’s largest generic pharmaceutical companies, with comprehensive API manufacturing capabilities. Their Meloxicam API production is compliant with global GMP standards, serving markets across North America, Europe, and emerging economies [1].

  2. Mundipharma International GmbH & Co. KG (Germany)
    Although primarily a pharmaceutical company, Mundipharma sources high-quality APIs from European API manufacturers. Their European suppliers adhere to stringent EMA standards, ensuring high-quality Meloxicam supply [2].

  3. Hunan Huaneng Pharmaceutical Co., Ltd. (China)
    A significant Chinese API manufacturer with GMP-certified facilities producing Meloxicam. Their capacity supports both domestic and international markets, with a focus on cost-efficiency and supply reliability [3].

  4. YG Healthcare, Ltd. (India)
    Specializes in NSAID APIs, including Meloxicam, with manufacturing facilities inspected by global regulatory agencies, including the US FDA and EMA [4].

Regulatory and Quality Considerations

Key suppliers maintain compliance with major pharmacopeias—USP, EP, and JP—and hold certification from regulatory authorities such as the US FDA, EMA, and WHO prequalification programs. Suppliers with validated manufacturing processes and GMP certification are preferred for ensuring consistent quality.


Overview of Rizatriptan Benzoate Suppliers

Market Dynamics and Manufacturing Hubs

Rizatriptan Benzoate APIs are primarily produced by Indian and Chinese manufacturers, with some European players supplying high-grade APIs. The synthesis of Rizatriptan benzoate involves complex chemical processes requiring specialized expertise.

Key Suppliers of Rizatriptan Benzoate

  1. Sun Pharmaceutical Industries Ltd. (India)
    Sun Pharma is a key supplier in the global Rizatriptan market, offering APIs that comply with international pharmacopeia standards. Their manufacturing facilities are routinely inspected by US FDA, ensuring high quality [1].

  2. Jiangsu Hengrui Medicine Co., Ltd. (China)
    As a leading Chinese pharmaceutical company focusing on CNS disorders, Hengrui produces Rizatriptan Benzoate APIs under strict GMP conditions, exporting primarily to Asian markets but also to global partners [5].

  3. Sino Biopharmaceutical Limited (Hong Kong/China)
    This producer supplies Rizatriptan Benzoate APIs to multinational pharmaceutical companies, maintaining compliance with international quality certifications [6].

  4. Dr. Reddy’s Laboratories (India)
    A prominent Indian manufacturer with a proven track record of supplying high-quality Rizatriptan APIs globally. Their plants are certified by US FDA, EMA, and other agencies, highlighting product reliability [7].

Regulatory and Certification Standards

Suppliers with US FDA, EMA, or WHO prequalification certifications are highly preferred. The complexity of Rizatriptan’s synthesis underscores the importance of suppliers with demonstrated process control and quality assurance measures.


Market Considerations and Supply Chain Risks

Regional Concentration and Dependency

The heavy reliance on Indian and Chinese suppliers creates potential risks, including geopolitical uncertainties, supply disruptions, and regulatory challenges. Diversifying supplier base and sourcing from multiple regions can mitigate these vulnerabilities.

Regulatory Compliance

Ensuring suppliers hold current GMP certifications and meet International Conference on Harmonisation (ICH) standards is essential for market access. Regular audits and batch testing confirm adherence and help preempt regulatory liabilities.

Emerging Suppliers and Market Entry

New entrants from Europe and other regions are increasingly certified to supply Meloxicam and Rizatriptan APIs, driven by stricter regulatory compliance and quality expectations. Engaging with these suppliers can offer market stability and potential cost advantages.


Key Players Summary Table

Drug Leading Suppliers Key Markets Regulatory Certifications Notes
Meloxicam Sun Pharma, Mundipharma, Hunan Huaneng, YG Healthcare Global GMP, USP, EP, JP Large capacity, established presence
Rizatriptan Benzoate Sun Pharma, Jiangsu Hengrui, Dr. Reddy’s, Sino Biopharmaceutical Global GMP, USFDA, EMA Synthesis complexity, quality focus

Conclusion

Reliable procurement of Meloxicam and Rizatriptan Benzoate APIs hinges on selecting suppliers with proven quality certifications, manufacturing scale, and regulatory compliance. Indian and Chinese manufacturers dominate this landscape, with established players like Sun Pharma leading globally. Diversification, rigorous Quality Assurance (QA), and ongoing due diligence are critical for pharmaceutical companies seeking secure, cost-effective supplies.


Key Takeaways

  • The global Meloxicam market is primarily supplied by Indian, Chinese, and European manufacturers, with Sun Pharma as a prominent leader.
  • Rizatriptan Benzoate suppliers include Indian and Chinese API producers, with high compliance standards being a critical determinant.
  • Supply chain resilience relies on diversification and continuous quality assurance of suppliers compliant with GMP and ICH standards.
  • Regulatory certifications, especially US FDA and EMA approvals, significantly influence supplier selection.
  • Emerging Asian manufacturers and regional suppliers present opportunities for cost savings and supply stability, provided they maintain stringent quality standards.

FAQs

1. Are Indian API manufacturers preferred for Meloxicam and Rizatriptan Benzoate?
Yes. Indian API manufacturers like Sun Pharma and Dr. Reddy’s are preferred due to their extensive capacity, regulatory compliance, and cost competitiveness. Their GMP-certified facilities ensure product quality suitable for international markets.

2. How do regulatory certifications impact supplier selection?
Certifications like US FDA, EMA, and WHO prequalification signify adherence to strict manufacturing and quality standards. They are critical for ensuring product safety, efficacy, and market acceptance, especially in regulated markets like the US and Europe.

3. What are the risks associated with geographic concentration of suppliers?
Dependence on suppliers from limited regions (notably India and China) exposes companies to regulatory, geopolitical, and supply chain disruptions. Diversification helps mitigate these risks.

4. How does the complexity of Rizatriptan Benzoate synthesis affect supplier reliability?
The complex chemical synthesis of Rizatriptan requires specialized expertise and process controls. Suppliers with demonstrated capability and robust QA systems are more reliable for consistent, high-quality APIs.

5. What emerging trends are influencing API supplier sourcing?
Increasing regulatory scrutiny and a push towards supply chain transparency are leading companies to explore European and North American manufacturers for higher assurance of quality and compliance, alongside traditional Asian suppliers.


Sources

  1. Sun Pharma Annual Report 2022.
  2. Mundipharma Corporate Overview.
  3. Hunan Huaneng Pharmaceutical GMP Certification.
  4. YG Healthcare API Documentation.
  5. Jiangsu Hengrui Medicine Annual Report.
  6. Sino Biopharmaceutical Certification Data.
  7. Dr. Reddy’s Annual Compliance Report.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.